newsfilter
← Latest News
GlobeNewswire·

Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults

– IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV, and was generally well tolerated, consistent with prior IVX-A12 Phase 1 data – SEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc.